MRI引导放疗用于直肠肿瘤的诊疗一体化应用(THUNDER 2)II期试验:中期安全性分析
THUNDER-2为单中心II期试验,评估MRI引导放疗(MRIgRT)治疗局部晚期直肠癌时,对ERI预测的非缓解者从第11次分割起加量至总剂量60.1 Gy的可行性与安全性;2021年3月至2022年11月入组33例(计划63例的52.4%),16例(50%)接受加量,仅标准治疗组1例(3.1%)出现急性3级腹泻、直肠炎和膀胱炎,两组毒性无显著差异(p=0.5463)。
要点
- 标准剂量55 Gy/25次至GTV与直肠系膜,引流淋巴结45 Gy,同步化疗。
- 第10次分割计算ERI,ERI高于13.1的非缓解者从第11次分割加量至总60.1 Gy。
- 16例(50%)接受加量,仅标准组1例(3.1%)出现急性3级腹泻、直肠炎和膀胱炎。
核心结论
- 对ERI预测为非缓解者的局部晚期直肠癌患者,MRIgRT加量至60.1 Gy耐受良好,证实该方法的可行性与安全性。
- THUNDER-2试验的主要与次要终点将在全部计划患者入组后进行全面分析。
研究设计与样本
- THUNDER-2为单中心II期试验,评估MRI引导放疗在局部晚期直肠癌中的获益。
- 入组cT2-3、N0-2或cT4伴肛括约肌受累、N0-2a、M0且无高危特征的患者。
- 计划入组63例,本次中期分析纳入33例(52.4%),其中1例退出与治疗无关。
主要发现
- 2021年3月至2022年11月入组33例(计划63例的52.4%),16例(50%)接受剂量加量。
- 仅标准治疗组1例(3.1%)出现急性3级腹泻、直肠炎和膀胱炎。
- 两组毒性无显著差异(p=0.5463)。
关键数值与推荐
- MRIgRT标准剂量为GTV与直肠系膜55 Gy、直肠系膜与引流淋巴结45 Gy,25次分割,同步化疗。
- 采用0.35 T MRI进行模拟定位与每日摆位。
- 第10次分割计算ERI,ERI高于13.1的非缓解者从第11次分割起加量,总剂量达60.1 Gy。
- 急性毒性采用CTCAE v.5量表评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本次为中期分析,仅纳入计划63例中的33例(52.4%)。
- 主要与次要终点将在全部计划患者入组后进行全面分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The THUNDER-2 phase II single institutional trial investigates the benefits of MRI-guided radiotherapy (MRIgRT) in treating locally advanced rectal cancer (LARC). This study focuses on evaluating the impact of escalating radiation therapy dose in non-responder patients using the Early Tumour Regression Index (ERI) for predicting complete response (CR). The trial's primary endpoint is to increase the CR rate in non-responders by 10% and assess the feasibility of the delta radiomics-based MRIgRT predictive model. This interim analysis assesses the feasibility and safety of the proposed MRIgRT dose escalation strategy in terms of acute toxicity (gastrointestinal, genitourinary and haematological) and treatment adherence. METHODS: Stage cT2-3, N0-2, or cT4 patients with anal sphincter involvement, N0-2a, M0, but without high-risk features were enrolled. MRIgRT treatment consisted of a standard dose of 55 Gy to the Gross Tumor Volume (GTV) and mesorectum, and 45 Gy to the mesorectum and drainage nodes in 25 fractions with concomitant chemotherapy. 0.35 T MRI was used for simulation imaging and daily alignment. ERI was calculated at the 10th fraction. Non-responders with an ERI above 13.1 received intensified dose escalation from the 11th fraction, resulting in a total dose of 60.1 Gy. Acute toxicity was assessed using the CTCAE v.5 scale. RESULTS: From March 2021 to November 2022, 33 out of the total number of 63 patients to be enrolled (52.4%) were included, with one withdrawal unrelated to treatment. Sixteen patients (50%) underwent dose escalation. Treatment was well tolerated, with only one patient (3.1%) in the standard treatment group experiencing acute Grade 3 diarrhea, proctitis, and cystitis. No significant differences in toxicity were observed between the two groups (p = 0.5463). CONCLUSIONS: MRIgRT treatment with dose escalation up to 60.1 Gy is well tolerated in LARC patients predicted as non-responders by ERI, confirming the feasibility and safety of this approach. The THUNDER-2 trial's primary and secondary endpoints will be fully analyzed when all planned patients will be enrolled.
引用
- Chiloiro G, Romano A, Cusumano D, et al. THeragnostic utilities for neoplastic DisEases of the rectum by MRI guided radiotherapy (THUNDER 2) phase II trial: interim safety analysis. Radiat Oncol. 2023. PMID: 37803322. doi:10.1186/s13014-023-02353-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。